Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | GRM5 | P41594 | 4/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL821839 | 0.91 | KMT2A (1.00) | KMT2AMEN1NPC1RAB9ARXFP1 | |
| SCHEMBL14294316 | 0.90 | KMT2A (0.66) | KMT2AMEN1KDM4ELMNARXFP1 | |
| SCHEMBL821844 | 0.85 | KDM4E (0.71) | KMT2AMEN1KDM4ELMNARAB9A | |
| SCHEMBL9753586 | 0.83 | RAB9A (0.88) | KMT2AMEN1NPC1RAB9AGRM5 | |
| SCHEMBL18658438 | 0.82 | GRM5 (0.60) | KMT2AMEN1KDM4ELMNARXFP1 | |
| SCHEMBL16899029 | 0.82 | KMT2A (0.75) | KMT2AMEN1NPC1RAB9ARXFP1 | |
| SCHEMBL28937146 | 0.81 | KMT2A (0.79) | KMT2AMEN1KDM4ELMNANPC1 | |
| SCHEMBL16899014 | 0.80 | KMT2A (0.77) | KMT2AMEN1KDM4ENPC1RAB9A | |
| SCHEMBL23286796 | 0.79 | KMT2A (0.77) | KMT2AMEN1NPC1RAB9ARXFP1 | |
| SCHEMBL29738098 | 0.79 | KMT2A (0.77) | KMT2AMEN1NPC1RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| EP-1669068-B1 | Compounds effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | KMT2A 1974/4885MEN1 1260/4885KDM4E 2280/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | KMT2A 1974/4885MEN1 1260/4885KDM4E 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.